Australian researchers are working to make laboratory-grown red blood cells easier and cheaper to produce for patients with complex transfusion needs. The University of Queensland’s 29 September announcement describes a collaboration with Lifeblood and SMART CRC focused on manufacturing, rather than a new treatment available to patients.
The scale of the task is captured by a small quantity. UQ says the current process takes around three weeks to produce roughly a teaspoon of red blood cells. That is an illustration of today’s manufacturing constraint, not a production target sufficient for routine transfusion services. Growing cells successfully in a laboratory and making a dependable clinical supply are different achievements, with cost, consistency and safety all requiring attention.
The A$2.5 million collaboration is intended to improve that production process. In its project announcement, SMART CRC describes work on bioreactor and cell-processing approaches to improve growth and recovery of the desired cells. Its own description uses “a few teaspoons” for the three-week output, reinforcing that the volume is approximate. The partners’ shared objective is to overcome labour-intensive, expensive production rather than announce that the problem has already been solved.
Rare blood needs help explain why such work matters. Lifeblood’s rare-donor guidance explains that red blood cells carry many antigens, the proteins and sugars used to distinguish blood groups. Some patients need combinations that are difficult to find among donors. The familiar A, B, AB and O categories are therefore only part of the matching problem, and a diverse donor population remains important.
Manufacturing research has to preserve the qualities that make those cells useful. Increasing the volume in a vessel would mean little if the resulting cells were unsuitable, inconsistent or too costly to recover. A workable process needs repeatable outputs and quality checks, as well as a way to move from experimental batches to dependable production. Those requirements explain why an apparently simple goal, making more cells, becomes a substantial engineering and biological problem.
International clinical research illustrates another step that cannot be skipped. The UK’s RESTORE trial is a phase-one study comparing small doses of manufactured and donated red blood cells in healthy volunteers. Its design examines how the cells recover and survive in circulation, and the trial page says recruitment is closed. An NHSBT research update says follow-up is complete, with results expected in 2026 or 2027. It is separate from the Australian collaboration and does not establish that a full manufactured transfusion is ready for routine Australian care.
Any future Australian clinical use would need evidence beyond manufacturing output. The partners identify further clinical testing and regulatory requirements before such cells could become a treatment option. Potential value for patients with rare types or repeated transfusion needs remains a research objective. A larger batch, by itself, would not demonstrate better patient outcomes or remove the need to assess how the cells behave after transfusion.
Blood donation continues to support patients while that research proceeds. Lifeblood maintains rare-donor arrangements and works with international partners when a suitable match is difficult to obtain. The collaboration’s most meaningful next milestones will be reproducible production, lower costs and evidence supporting further development. For now, it is an effort to strengthen a possible future supply for specialised needs, with existing donation and transfusion services remaining essential.
